Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): A proposal of the Austrian CML platform

Wiener Klinische Wochenschrift

Volumn 120, Issue 21-22, 2008, Pages 697-709

  Valent, Peter ^a,b   Lion, Thomas ^c,d   Wolf, Dominik ^e   Sillaber, Christian ^a   Agis, Hermine ^a   Petzer, Andreas ^f   Lang, Alois ^a   Kalhs, Peter ^a   Geissler, Dietmar ^g   Greil, Richard ^h   Linkesch, Werner ⁱ   Burgstaller, Sonja ^j   Thaler, Josef ^j   Gastl, Günther ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Labdia Labordiagnostik   (Austria)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^g GENERAL HOSPITAL KLAGENFURT   (Austria)

^h PARACELSUS MEDICAL UNIVERSITY   (Austria)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j Hospital Wels Grieskirchen   (Austria)

more..

Author keywords

BCR ABL mutations; CML; Dasatinib; Imatinib; Nilotinib

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; ALPHA INTERFERON; AP 23848; AURORA KINASE INHIBITOR; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DIURETIC AGENT; DORAMAPIMOD; EVEROLIMUS; GLUCOCORTICOID; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; ON 01910; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LABORATORY TEST; LOW DRUG DOSE; PERICARDIAL EFFUSION; PHYSICAL EXAMINATION; PLEURA EFFUSION; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THORACOCENTESIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ALGORITHM; AUSTRIA; DECISION SUPPORT SYSTEM; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRACTICE GUIDELINE;

ALGORITHMS; AUSTRIA; DECISION SUPPORT SYSTEMS, CLINICAL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 58149296508     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-1100-8     Document Type: Review

References (120)

1. PC Nowell DA Hungerford 1960 A minute chromosome in human granulocytic leukemia Science 132 1497
2. JD Rowley 1973 A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290 293
3. A de Klein AG van Kessel G Grosveld CR Bartram A Hagemeijer D Bootsma 1982 A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia Nature 300 765 767
4. GQ Daley RA Van Etten D Baltimore 1990 Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 824 830
5. M Wetzler M Talpaz RA Van Etten C Hirsh-Ginsberg M Beran R Kurzrock 1993 Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation J Clin Invest 92 1925 1939
6. J Cortes H Kantarjian 2003 Advanced-phase chronic myeloid leukemia Semin Hematol 40 79 86
7. FJ Giles JE Cortes HM Kantarjian SM O'Brien 2004 Accelerated and blastic phases of chronic myelogenous leukemia Hematol Oncol Clin North Am 18 753 774
8. JE Cortes M Talpaz S O'Brien S Faderl G Garcia-Manero A Ferrajoli 2006 Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal Cancer 106 1306 1315
9. JM Goldman JF Apperley L Jones R Marcus AW Goolden R Batchelor 1986 Bone marrow transplantation for patients with chronic myeloid leukemia N Engl J Med 314 202 207
10. A Gratwohl J Hermans JM Goldman W Arcese E Carreras A Devergie 1998 Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Lancet 352 1087 1092
11. G Silberman MG Crosse EA Peterson RC Weston MM Horowitz FR Appelbaum 1994 Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries N Engl J Med 331 1063 1067
12. MH Cohen G Williams JR Johnson J Duan J Gobburu A Rahman 2002 Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clin Cancer Res 8 935 942
13. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645 652
14. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004
15. TP Hughes J Kaeda S Branford Z Rudzki A Hochhaus ML Hensley 2003 Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423 1432
16. BJ Druker CL Sawyers H Kantarjian DJ Resta SF Reese JM Ford 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 1038 1042
17. M Talpaz RT Silver BJ Druker JM Goldman C Gambacorti-Passerini F Guilhot 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 1928 1937
18. CL Sawyers A Hochhaus E Feldman JM Goldman CB Miller OG Ottmann 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530 3539
19. DJ Barnes JV Melo 2006 Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia Cell Cycle 5 2862 2866
20. X Jiang Y Zhao C Smith M Gasparetto A Turhan A Eaves C Eaves 2007 Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies Leukemia 21 926 935
21. Valent P (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol (in press)
22. P Rousselot F Huguet D Rea L Legros JM Cayuela O Maarek O Blanchet G Marit E Gluckman J Reiffers M Gardembas FX Mahon 2007 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 58 60
23. T Darkow HJ Henk SK Thomas W Feng JF Baladi GA Goldberg A Hatfield J Cortes 2007 Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia Pharmacoeconomics 25 481 496
24. E Weisberg JD Griffin 2000 Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines Blood 95 3498 3505
25. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876 880
26. NP Shah JM Nicoll B Nagar ME Gorre RL Paquette J Kuriyan 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 117 125
27. S Branford Z Rudzki S Walsh A Grigg C Arthur K Taylor 2002 High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 3472 3475
28. N von Bubnoff F Schneller C Peschel J Duyster 2002 BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 359 487 491
29. FX Mahon F Belloc V Lagarde C Chollet F Moreau-Gaudry J Reiffers 2003 MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models Blood 101 2368 2373
30. J Thomas L Wang RE Clark M Pirmohamed 2004 Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 3739 3745
31. T Illmer M Schaich U Platzbecker J Freiberg-Richter U Oelschlägel M von Bonin 2004 P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate Leukemia 18 401 408
32. R Villuendas JL Steegmann M Pollán L Tracey A Granda E Fernández-Ruiz 2006 Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach Leukemia 20 1047 1054
33. HM Kantarjian M Talpaz F Giles S O'Brien J Cortes 2006 New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance Ann Intern Med 145 913 923
34. NP Shah C Tran FY Lee P Chen D Norris CL Sawyers 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401
35. E Weisberg PW Manley W Breitenstein J Brüggen SW Cowan-Jacob A Ray 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129 141
36. A Yokota S Kimura S Masuda E Ashihara J Kuroda K Sato 2007 INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood 109 306 314
37. M Puttini AM Coluccia F Boschelli L Cleris E Marchesi A Donella-Deana S Ahmed S Redaelli R Piazza V Magistroni F Andreoni L Scapozza F Formelli C Gambacorti-Passerini 2006 In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells Cancer Res 66 11314 11322
38. G Martinelli S Soverini G Rosti D Cilloni M Baccarani 2005 New tyrosine kinase inhibitors in chronic myeloid leukemia Haematologica 90 534 541
39. E Weisberg PW Manley SW Cowan-Jacob A Hochhaus JD Griffin 2007 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia Nat Rev Cancer 7 345 356
40. A Quintás-Cardama H Kantarjian J Cortes 2007 Flying under the radar: the new wave of BCR-ABL inhibitors Nat Rev Drug Discov 6 834 848
41. JM Hernández R González-Sarmiento C Martin M González I Sánchez J Corral A Orfao MC Cañizo JF San Miguel A López-Borrasca 1991 Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia Br J Haematol 79 408 414
42. ML Haung CH Ho 1998 Diagnostic value of an automatic hematology analyzer in patients with hematologic disorders Adv Ther 15 137 141
43. S Ducrest F Meier C Tschopp R Pavlovic CA Dahinden 2005 Flowcytometric analysis of basophil counts in human blood and inaccuracy of hematology analyzers Allergy 60 1446 1450
44. JF Lesesve M Benbih T Lecompte 2005 Accurate basophils counting: not an easy goal! Clin Lab Haematol 27 143 144
45. HJ Bühring PJ Simmons M Pudney R Müller D Jarrossay A van Agthoven M Willheim W Brugger P Valent L Kanz 1999 The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors Blood 94 2343 2356
46. H Agis MT Krauth A Böhm I Mosberger L Müllauer I Simonitsch-Klupp AF Walls HP Horny P Valent 2006 Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders Am J Clin Pathol 125 273 281
47. H Agis MT Krauth I Mosberger L Müllauer I Simonitsch-Klupp LB Schwartz D Printz A Böhm G Fritsch HP Horny P Valent 2006 Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7 J Clin Pathol 59 396 402
48. H Agis WR Sperr S Herndlhofer H Semper H Pirc-Danoewinata OA Haas C Mannhalter H Esterbauer K Geissler C Sillaber U Jäger P Valent 2007 Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571) Ann Oncol 18 1834 1841
49. P Valent H Agis W Sperr C Sillaber HP Horny 2008 Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia Leuk Lymphoma 49 635 638
50. G Buesche A Ganser B Schlegelberger N von Neuhoff D Gadzicki H Hecker O Bock B Frye H Kreipe 2007 Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia Leukemia 21 2420 2427
51. D Primo MD Tabernero A Rasillo JM Sayagués AB Espinosa MC Chillón R Garcia-Sanz N Gutierrez M Giralt A Hagemeijer JF San Miguel A Orfao 2003 Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities Leukemia 17 1124 1129
52. N Douet-Guilbert F Morel S Quemener A Maguer MJ Le Bris P Morice C Berthou M De Braekeleer 2006 Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia Cancer Genet Cytogenet 170 89 92
53. L Babicka Z Zemanova L Pavlistova J Brezinova S Ransdorfova L Houskova J Moravcova H Klamova K Michalova 2006 Complex chromosomal rearrangements in patients with chronic myeloid leukemia Cancer Genet Cytogenet 168 22 29
54. M Krulik N Smadja A de Gramont G Gonzalez-Canali AA Audebert C Dray P Brissaud J Debray 1987 Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional chromosomal abnormalities during disease evolution Cancer 60 974 979
55. SS Farag AS Ruppert K Mrózek AJ Carroll MJ Pettenati MM Le Beau BL Peterson BL Powell H Ozer RT Silver RA Larson CD Bloomfield Cancer and Leukemia Group B study 2004 Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study Int J Oncol 25 143 151
56. MW Deininger J Cortes R Paquette B Park A Hochhaus M Baccarani R Stone T Fischer H Kantarjian D Niederwieser C Gambacorti-Passerini C So I Gathmann JM Goldman D Smith BJ Druker F Guilhot 2007 The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells Cancer 110 1509 1519
57. A Hochhaus A Weisser P La Rosée M Emig MC Müller S Saussele A Reiter C Kuhn U Berger R Hehlmann NC Cross 2000 Detection and quantification of residual disease in chronic myelogenous leukemia Leukemia 14 998 1005
58. MC Müller N Gattermann T Lahaye MW Deininger A Berndt S Fruehauf A Neubauer T Fischer DK Hossfeld F Schneller SW Krause C Nerl HG Sayer OG Ottmann C Waller W Aulitzky P le Coutre M Freund K Merx P Paschka H König S Kreil U Berger H Gschaidmeier R Hehlmann A Hochhaus 2003 Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C Leukemia 17 2392 2400
59. T Hughes M Deininger A Hochhaus S Branford J Radich J Kaeda M Baccarani J Cortes NC Cross BJ Druker J Gabert D Grimwade R Hehlmann S Kamel-Reid JH Lipton J Longtine G Martinelli G Saglio S Soverini W Stock JM Goldman 2006 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28 37
60. D Douer I Fabian MJ Cline 1983 Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders Br J Haematol 54 373 381
61. JE Sokal EB Cox M Baccarani S Tura GA Gomez JE Robertson CY Tso TJ Braun BD Clarkson F Cervantes 1984 Prognostic discrimination in "good-risk" chronic granulocytic leukemia Blood 63 789 799
62. J Hasford M Pfirrmann R Hehlmann NC Allan M Baccarani JC Kluin-Nelemans G Alimena JL Steegmann H Ansari 1998 A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group J Natl Cancer Inst 90 850 858
63. HM Kantarjian MJ Keating TL Smith M Talpaz KB McCredie 1990 Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia Am J Med 88 1 8
64. J Hasford M Pfirrmann R Hehlmann M Baccarani F Guilhot FX Mahon HC Kluin-Nelemans K Ohnishi J Thaler JL Steegmann 2003 Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy Semin Hematol 40 4 12
65. B Peng M Hayes D Resta A Racine-Poon BJ Druker M Talpaz CL Sawyers M Rosamilia J Ford P Lloyd R Capdeville 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 935 942
66. DL White VA Saunders P Dang J Engler A Venables S Zrim A Zannettino K Lynch PW Manley T Hughes 2007 Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood 110 4064 4072
67. S Picard K Titier G Etienne E Teilhet D Ducint MA Bernard R Lassalle G Marit J Reiffers B Begaud N Moore M Molimard FX Mahon 2007 Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 3496 3499
68. RA Larson BJ Druker F Guilhot SG O'Brien GJ Riviere T Krahnke I Gathmann Y Wang IRIS (International Randomized Interferon vs STI571) Study Group 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 4028
69. T Lange T Bumm S Otto HK Al-Ali I Kovacs D Krug T Köhler R Krahl D Niederwieser MW Deininger 2004 Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy Haematologica 89 49 57
70. J Goldman 2005 Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era Curr Opin Hematol 12 33 39
71. G Martinelli I Lacobucci S Soverini D Cilloni G Saglio F Pane M Baccarani 2006 Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management Hematol Oncol 24 196 204
72. S Branford NC Cross A Hochhaus J Radich G Saglio J Kaeda J Goldman T Hughes 2006 Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia Leukemia 20 1925 1930
73. F Bao R Munker C Lowery S Martin R Shi DM Veillon JD Cotelingam ML Nordberg 2007 Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias Mol Diagn Ther 11 239 245
74. RD Press C Galderisi R Yang C Rempfer SG Willis MJ Mauro BJ Druker MW Deininger 2007 A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response Clin Cancer Res 13 6136 6143
75. MC Müller G Saglio F Lin H Pfeifer RD Press RR Tubbs P Paschka E Gottardi SG O'Brien OG Ottmann H Stockinger L Wieczorek K Merx H König U Schwindel R Hehlmann A Hochhaus 2007 An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR Haematologica 92 970 973
76. MC Müller P Erben G Saglio E Gottardi CG Nyvold T Schenk T Ernst S Lauber J Kruth R Hehlmann A Hochhaus European LeukemiaNet 2008 Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories Leukemia 22 96 102
77. FX Gruber T Lamark A Anonli MA Sovershaev M Olsen T Gedde-Dahl H Hjort-Hansen B Skogen 2005 Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL Leukemia 19 2159 2165
78. Preuner S, Denk D, Frommlet F, Nesslboeck M, Lion T (2008) Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia (in press)
79. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum J Apperley F Cervantes J Cortes M Deininger A Gratwohl F Guilhot M Horowitz T Hughes H Kantarjian R Larson D Niederwieser R Silver R Hehlmann European LeukemiaNet 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 1820
80. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao CL Sawyers 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876 880
81. C Roche-Lestienne C Preudhomme 2003 Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment Semin Hematol 40 S2 80 82
82. N von Bubnoff PW Manley J Mestan J Sanger C Peschel J Duyster 2006 Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood 108 1328 1333
83. E Jabbour H Kantarjian D Jones M Talpaz N Bekele S O'Brien X Zhou R Luthra G Garcia-Manero F Giles MB Rios S Verstovsek J Cortes 2006 Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 1767 1773
84. T O'Hare CA Eide MW Deininger 2007 Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2242 2249
85. JM Goldman 2007 How I treat chronic myeloid leukemia in the imatinib era Blood 110 2828 2837
86. E Jabbour JE Cortes FJ Giles S O'Brien HM Kantarjian 2007 Current and emerging treatment options in chronic myeloid leukemia Cancer 109 2171 2181
87. E Jabbour J Cortes H Kantarjian S Giralt BS Andersson F Giles E Shpall P Kebriaei R Champlin M de Lima 2007 Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity Cancer 110 340 344
88. H Menzel N von Bubnoff A Hochhaus C Haferlach C Peschel J Duyster 2007 Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib Bone Marrow Transplant 40 83 84
89. NP Shah BJ Skaggs S Branford TP Hughes JM Nicoll RL Paquette CL Sawyers 2007 Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency J Clin Invest 117 2562 2569
90. J Cortes E Jabbour H Kantarjian CC Yin J Shan S O'Brien G Garcia-Manero F Giles M Breeden N Reeves WG Wierda D Jones 2007 Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 4005 4011
91. M Baranska K Lewandowski M Gniot M Iwola M Lewandowska M Komarnicki 2008 Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene J Appl Genet 49 201 203
92. S Soverini S Colarossi A Gnani F Castagnetti G Rosti C Bosi S Paolini M Rondoni PP Piccaluga F Palandri P Giannoulia G Marzocchi S Luatti N Testoni I Iacobucci D Cilloni G Saglio M Baccarani G Martinelli 2007 Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain Haematologica 92 401 404
93. T O'Hare CA Eide MW Deininger 2008 New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check Expert Opin Investig Drugs 17 865 878
94. E Abruzzese M Cantonetti L Morino G Orlandi A Tendas MI Del Principe 2003 CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports J Clin Oncol 21 4256 4258
95. S Bujassoum J Rifkind JH Lipton 2004 Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy Leuk Lymphoma 45 401 403
96. ME Rytting WG Wierda 2004 Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy Leuk Lymphoma 45 1623 1626
97. M Matsuda Y Morita T Shimada J Miyatake C Hirase M Tanaka 2005 Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate Int J Hematol 81 307 309
98. HJ Kim CW Jung K Kim JS Ahn WS Kim K Park 2006 Isolated blast crisis in CNS in a patient with chronic myelogenous leukaemia maintaining major cytogenetic response after imatinib J Clin Oncol 24 4028 4029
99. KJ Aichberger S Herndlhofer H Agis WR Sperr H Esterbauer W Rabitsch P Knöbl OA Haas R Thalhammer I Schwarzinger C Sillaber U Jäger P Valent 2007 Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy Eur J Clin Invest 37 808 813
100. AL Petzer E Gunsilius M Hayes G Stockhammer HC Duba F Schneller 2002 Low concentrations of STI571 in the cerebrospinal fluid: a case report Br J Haematol 117 623 625
101. N Takayama N Sato SG O'Brien Y Ikeda S Okamoto 2002 Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid Br J Haematol 119 106 108
102. NC Wolff JA Richardson M Egorin RL Ilaria 2003 The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia Blood 101 5010 5013
103. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood (in press)
104. MK Andersen J Pedersen-Bjergaard L Kjeldsen IH Dufva K Brøndum-Nielsen 2002 Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8 Leukemia 16 1390 1393
105. P Meeus H Demuynck P Martiat L Michaux E Wouters A Hagemeijer 2003 Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib Leukemia 17 465 467
106. J Medina H Kantarjian M Talpaz S O'Brien G Garcia-Manero F Giles MB Rios K Hayes J Cortes 2003 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Cancer 98 1905 1911
107. T Bumm C Müller HK Al-Ali K Krohn P Shepherd E Schmidt S Leiblein C Franke E Hennig T Friedrich R Krahl D Niederwieser MW Deininger 2003 Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority Blood 101 1941 1949
108. C Terre V Eclache P Rousselot M Imbert C Charrin C Gervais MJ Mozziconacci O Maarek H Mossafa N Auger N Dastugue P Talmant J Van den Akker C Leonard F N'Guyen Khac F Mugneret F Viguié M Lafage-Pochitaloff JN Bastie GL Roux F Nicolini F Maloisel N Vey G Laurent C Recher M Vigier Y Yacouben S Giraudier JP Vernant B Salles J Roussi S Castaigne V Leymarie G Flandrin M Lessard France Intergroupe pour la Leucemie Myeloide Chronique 2004 Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia Leukemia 18 1340 1346
109. Y Lin H Bruyère DE Horsman T Pantzar MJ Barnett DE Hogge TJ Nevill SH Nantel HJ Sutherland CL Toze JD Shepherd JC Lavoie KW Song CA Smith DL Forrest 2006 Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors Cancer Genet Cytogenet 170 16 23
110. A Fabarius C Haferlach MC Müller P Erben T Lahaye M Giehl O Frank W Seifarth R Hehlmann A Hochhaus 2007 Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure Haematologica 92 834 837
111. NP Shah HM Kantarjian DW Kim D Réa PE Dorlhiac-Llacer JH Milone J Vela-Ojeda RT Silver HJ Khoury A Charbonnier N Khoroshko RL Paquette M Deininger RH Collins I Otero T Hughes E Bleickardt L Strauss S Francis A Hochhaus 2008 Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia J Clin Oncol 26 3204 3212
112. H Kantarjian R Pasquini N Hamerschlak P Rousselot J Holowiecki S Jootar T Robak N Khoroshko T Masszi A Skotnicki A Hellmann A Zaritsky A Golenkov J Radich T Hughes A Countouriotis N Shah 2007 Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial Blood 109 5143 5150
113. A Quintás-Cardama H Kantarjian S O'Brien G Borthakur J Bruzzi R Munden J Cortes 2007 Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure J Clin Oncol 25 3908 3914
114. A Bergeron D Réa V Levy C Picard V Meignin J Tamburini H Bruzzoni-Giovanelli F Calvo A Tazi P Rousselot 2007 Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series Am J Respir Crit Care Med 176 814 818
115. H Kantarjian F Giles L Wunderle K Bhalla S O'Brien B Wassmann C Tanaka P Manley P Rae W Mietlowski K Bochinski A Hochhaus JD Griffin D Hoelzer M Albitar M Dugan J Cortes L Alland OG Ottmann 2006 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2542 2551
116. HM Kantarjian F Giles N Gattermann K Bhalla G Alimena F Palandri GJ Ossenkoppele FE Nicolini SG O'Brien M Litzow R Bhatia F Cervantes A Haque Y Shou DJ Resta A Weitzman A Hochhaus P le Coutre 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540 3546
117. U Rix O Hantschel G Dürnberger LL Remsing Rix M Planyavsky NV Fernbach I Kaupe KL Bennett P Valent J Colinge T Köcher G Superti-Furga 2007 Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110 4055 4063
118. M Bantscheff D Eberhard Y Abraham S Bastuck M Boesche S Hobson T Mathieson J Perrin M Raida C Rau V Reader G Sweetman A Bauer T Bouwmeester C Hopf U Kruse G Neubauer N Ramsden J Rick B Kuster G Drewes 2007 Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotechnol 25 1035 1044
119. T O'Hare DK Walters EP Stoffregen DW Sherbenou MC Heinrich MW Deininger BJ Druker 2005 Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib Clin Cancer Res 11 6987 6993
120. E Weisberg L Catley RD Wright D Moreno L Banerji A Ray 2007 Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias Blood 109 2112 2120